Terapi hormon maskulin: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
WanaraLima (bicara | kontrib) Fitur saranan suntingan: 3 pranala ditambahkan. |
|||
(4 revisi perantara oleh 3 pengguna tidak ditampilkan) | |||
Baris 1:
{{Penyangkalan medis}}{{see also|Terapi hormon transgender}}
{{Templat sisi transgender}}
'''Terapi hormon maskulin''' (''masculinizing hormone therapy''), atau disebut juga '''terapi hormon
{{TOC limit|3}}
Baris 20:
== Kontraindikasi ==
Kontraindikasi absolut dari terapi hormon maskulin mencakup [[kehamilan]], gangguan pada [[arteri koroner]] yang tidak stabil, [[polisitemia]]/[[eritrositosis]] yang belum ditangani dengan tingkat [[hematokrit]] lebih dari 50%, dan riwayat kanker yang terkait dengan hormon seperti [[kanker payudara]]. Pemeriksaan juga sebaiknya dilakukan terkait [[sindrom ovarium polisistik]], [[tekanan darah]], diabetes, kekebalan tubuh, penyakit [[kardiovaskular]] dan [[serebrovaskular]], serta penyakit terkait [[estrogen]] lain, seperti [[migren]].{{sfn|Hembree, et al.|2017|p=3886}}{{sfn|WPATH|2011|p=45}}{{sfn|UCSF Transgender Care|2016|p=55-56}}
== Risiko dan efek samping ==
Penelitian telah menunjukkan bahwa terapi hormon transgender pada orang dewasa aman untuk dilakukan di bawah pengawasan tenaga medis profesional.<ref>{{Cite journal|last=Weinand|first=J. D.|last2=Safer|first2=J. D.|date=2015|year=|title=Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals|url=|journal=Journal of Clinical & Translational Endocrinology|language=|volume=2|issue=2|pages=55–60|doi=10.1016/j.jcte.2015.02.003}}</ref>
== Metode ==
Baris 42:
* {{cite journal|last=Humbree |first=W. C. |author2=et al. |ref={{harvid|Humbree, et al.|2017}} |date=2017 |title=Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline |journal=The Journal of Clinical Endocrinology & Metabolism |volume=102 |issue=11 |pages=3869–3903|doi=10.1210/jc.2017-01658}}
* {{cite book |author=UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco |ref={{harvid|USCF Transgender Care|2016}}|title=Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People |editon=2 |editor1-last=Deutsch |editor1-first=M. B. |date=2016 |publisher=UCSF Transgender Care |url=https://transcare.ucsf.edu/guidelines}}
* {{cite book |ref={{harvid|WPATH|2011}} |title=Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People 7th Version |author=World Professional Association for Transgender Health |year=2011 |url=http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&pk_association_webpage=3926 |access-date=2019-06-29 |archive-date=2014-01-28 |archive-url=https://web.archive.org/web/20140128104021/http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&pk_association_webpage=3926 |dead-url=yes }}
{{DEFAULTSORT:Terapi Hormon Maskulin}}
|